Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ · Healthcare
Recursion Pharmaceuticals, Inc. EBITDA 2019–2025
Recursion Pharmaceuticals, Inc. annual/quarterly ebitda history and growth rate from 2019 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Recursion Pharmaceuticals, Inc. ebitda for the quarter ending March 31, 2026 was -108.8 M, a 36.74% decrease year-over-year.
- Recursion Pharmaceuticals, Inc. ebitda for the twelve months ending March 31, 2026 was -436.0 M.
- Recursion Pharmaceuticals, Inc. annual ebitda for 2025 was -564.4 M, a 27.55% increase from 2024.
- Recursion Pharmaceuticals, Inc. annual ebitda for 2024 was -442.5 M, a 35.88% increase from 2023.
- Recursion Pharmaceuticals, Inc. annual ebitda for 2023 was -325.7 M, a 39.19% increase from 2022.
- Recursion Pharmaceuticals, Inc. annual ebitda for 2022 was -234.0 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Recursion Pharmaceuticals, Inc. EBITDA — FAQ
Recursion Pharmaceuticals, Inc. (RXRX) ebitda over the last 7 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see RXRX's ebitda history?
The chart and table above show Recursion Pharmaceuticals, Inc.'s ebitda by year and by quarter, including the growth rate.